- The disease
- Acute respiratory infections (ARIs) are a broad category of illnesses affecting the nose, throat, airways, or lungs caused by either bacterial or viral pathogens. Distinguishing bacterial from viral infection at the point of care is clinically relevant because antibiotics are effective only against bacteria. Unnecessary antibiotic prescribing contributes to antimicrobial resistance, a recognised global public health concern. ARIs are among the most common reasons patients present to primary care and emergency settings.
- What the asset is trying to do
- FebriDx is a point-of-care rapid test that measures host immune response proteins in a fingerstick blood sample to differentiate bacterial from viral infection in patients with ARIs. The test detects two biomarkers, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), simultaneously (per Lumos Diagnostics product documentation). Unlike pathogen-based rapid tests that identify a specific virus or bacterium, FebriDx assesses the patient's own immune response to indicate the type of infection present. The test holds a CE Mark, indicating conformity with applicable European Union regulatory requirements.
- What the trial is measuring, and why it matters
- The ongoing pediatric validation study (NCT07211997) is designed to evaluate FebriDx performance in children with ARIs, a population that was not the primary focus of earlier adult studies. A previously completed method comparison study (NCT06746259, primary completion August 2025) assessed FebriDx results against reference laboratory methods (per ClinicalTrials.gov NCT06746259). Validation studies in diagnostics typically measure performance metrics such as sensitivity, specificity, and agreement with a reference standard, which inform regulatory submissions and clinical adoption.
- Efficacy benchmarks in this setting
- Approved laboratory-based testing approaches for ARI bacterial versus viral differentiation include procalcitonin assays and CRP testing, for which published performance data exist in peer-reviewed literature. For example, a meta-analysis by Schuetz et al. (BMJ 2012) reported summary sensitivity and specificity figures for procalcitonin in distinguishing bacterial from viral lower respiratory tract infections, though performance varies by cut-off and clinical context. The DISRUPT trial (NCT02018198, completed) generated performance data for FebriDx in adults; those adult figures are not statistically comparable to pediatric performance data being collected in NCT07211997, which targets a distinct patient population with different reference ranges and immune responses.
- Commercial context
- FebriDx holds a CE Mark for use in Europe and has been the subject of US commercial activity, as referenced in Lumos Diagnostics investor presentations dated June 2026 (per ASX announcements). The US Food and Drug Administration (FDA) has not granted 510(k) clearance or de novo authorisation for FebriDx as of the most recent available public information; the US regulatory status should be confirmed from current FDA databases. FebriDx is described as the lead asset of Lumos Diagnostics (ASX: LDX) based on the company's public communications. No licensing or distribution deal financial terms have been disclosed in the input data provided.